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Myopathy associated BAG3 mutations lead to
protein aggregation by stalling Hsp70 networks
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Steven S. Scherer6, Federica F. Morelli9, Serena Carra1,9, Conrad C. Weihl3, Steven Bergink1,
Jason E. Gestwicki 2 & Harm H. Kampinga1
BAG3 is a multi-domain hub that connects two classes of chaperones, small heat shock
proteins (sHSPs) via two isoleucine-proline-valine (IPV) motifs and Hsp70 via a BAG
domain. Mutations in either the IPV or BAG domain of BAG3 cause a dominant form of
myopathy, characterized by protein aggregation in both skeletal and cardiac muscle tissues.
Surprisingly, for both disease mutants, impaired chaperone binding is not sufficient to explain
disease phenotypes. Recombinant mutants are correctly folded, show unaffected Hsp70
binding but are impaired in stimulating Hsp70-dependent client processing. As a con-
sequence, the mutant BAG3 proteins become the node for a dominant gain of function
causing aggregation of itself, Hsp70, Hsp70 clients and tiered interactors within the BAG3
interactome. Importantly, genetic and pharmaceutical interference with Hsp70 binding
completely reverses stress-induced protein aggregation for both BAG3 mutations. Thus, the
gain of function effects of BAG3 mutants act as Achilles heel of the HSP70 machinery.
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BAG3 is a multi-domain scaffolding protein composed of aWW domain, two isoleucine–proline–valine (IPV) motifs, aPxxP domain, and a C-terminal BAG domain (Fig. 1a),
enabling it to engage in multiple protein–protein interactions. It
is the only stress-inducible BAG-family member and highly
expressed in muscle1. Among the binding partners of BAG3 are
different classes of molecular chaperones; it binds to 14-3-3
proteins2,3, to Hsp70 (also called HSPAs) via its C-terminal BAG
domain, and to small heat shock proteins (also called HSPBs) via
its IPV motifs (Fig. 1a)1,4. Together, these molecular chaperones
play a crucial role in protein quality control (PQC)5,6. In this
process, Hsp70s rely on co-chaperones of the DNAJ- and HSPB-
families to deliver clients7, while nucleotide exchange factors
(NEFs), including BAG3, promote client release7. BAG3 is
thought to play a critical role because it can bind to Hsp70 and to
HSPBs simultaneously8,9, thereby forming a ternary complex.
This type of adapter activity is expected to be critical because
HSPBs lack enzymatic function and are not able to refold clients;
rather, they rely on collaboration with other ATP-driven cha-
perones, such as Hsp70s10. Thus, the proper timing and archi-
tecture of this multi-chaperone complex is likely extremely
important to ensure a proper chaperone function. Interestingly,
BAG3 is generally expressed at low levels in addition to being the
only stress-inducible member of the BAG-family of NEFs. In fact,
multiple types of stress can induce the expression of BAG311–13,
including mechanical stress as caused by muscle contraction14–16.
Several mutations in the individual components of the HSP70
machinery have been shown to cause disease17. Whereas no
disease-associated mutations have been found in Hsp70 genes,
suggesting that these may be incompatible with life, most so-
called chaperonopathies, are caused by mutations in either DnaJ
or HspB genes. The only two NEFs in which mutations are shown
to cause disease are SIL1 and BAG3. Mutations in the Sil1 gene,
the ER-resident NEF, causes Marinesco-Sjögren syndrome, which
is an autosomal recessive cerebellar ataxia associated with a
myopathy characterized by vacuoles and protein inclusions18.
Mutations in Bag3 also cause a spectrum of disease phenotypes1.
For example, a proline to leucine substitution at position 209
within the HSPB binding motif (referred to as BAG3P209L),
causes a dominant, progressive myofibrillar myopathy (MFM) in
which patients suffer from progressive muscle weakening, fol-
lowed by sudden death due to heart failure in early adulthood19.
A striking feature of this disease is the accumulation of protein
aggregates in patient muscle, suggesting a collapse of protein
homeostasis19,20. In addition, other missense mutations at the
same P209 position (P209Q or P209S) within the IPV motif have
been identified in multiple families with MFM and/or neuro-
pathy21,22. Because these BAG3 mutations lie in the second IPV
motif, loss of HSPB binding has been suggested as a molecular
mechanism underlying disease23,24. However, in this study we
report on a novel mutation in the BAG domain (BAG3P470S) as
the cause of MFM, in two unrelated families. This observation
calls into question whether the BAG3 mutants merely disrupt
HSPB binding. Therefore, we set out to study the mechanism by
which mutations in BAG3 protein drive such a devastating
disease.
In contrast to the initial expectation, we show that a disturbed
binding of BAG3 mutants to either HSPBs or Hsp70 does not
underlie the dramatic collapse of PQC. In fact, for both the
BAG3P209 and BAG3P470 mutants, binding to Hsp70 was found
to be required for the phenotypic effects. These mutations caused
aggregation of Hsp70 client protein and subsequent sequestration
of PQC–proteins into insoluble aggregates. Importantly, the
function of co-aggregating chaperones is severely hampered.
Together, these events lead to a self-perpetuating progressive
collapse of PQC. We found that the genetic or pharmacological
disruption of the interaction between the mutant BAG3 proteins
and Hsp70 is sufficient to revert this process. Thus, our data
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Fig. 1 Cytoplasmic protein aggregation by BAG3P209L. a Schematic representation of BAG3 depicting the WW domain, the IPV motifs, the PxxP domain
and the BAG domain. The disease-causing mutations P209L, P209Q, and P209S, and p470S are indicated with an arrow. The Hsp70-interaction disrupting
mutation R480A is indicated with an *. b Immunofluorescence pictures of myoblast expressing FLAG-BAG3WT or FLAG-BAG3P209L, using BAG3 (green)
or FLAG (red) antibodies. DAPI staining is shown in blue. Scale bar= 5 μm. c Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3P209L
using antibodies against BAG3 (green) and Lamin A/C (red). DAPI staining is shown in blue. Scale bar= 5 μm. d Immunofluorescence pictures of FLAG-
BAG3WT and FLAG-BAG3P209L expressing HeLa cells using BAG3 antibody (green) before and after detergent treatment prior to fixation. Scale bar=
5 μm. e Whole cell extracts (WCE) and NP-40 soluble and insoluble fractions of HEK293 cells expressing indicated FLAG-BAG3 variants. Western blot
against the indicated antibodies is shown. Source data are provided as a Source data file
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reveal how two different types of mutations in BAG3 lead to
MFM in a similar manner that goes beyond a simple loss of
function but is mediated by a dominant-gain of function on the
Hsp70 chaperone machines. These findings suggest that BAG3 in
particular, and maybe NEFs in general, are a potential Achilles
heel of the Hsp70 machinery, where minor malfunctioning results
in the entrapment of the whole chaperone complex with dis-
astrous consequences for protein homeostasis. Inhibiting the
BAG3–Hsp70 interaction using small molecules relieves this
collapse and offers the first potential strategy to help these
patients.
Results
HSPB binding is not linked to the BAG3P209L phenotype. It is
striking that several BAG3 mutations that lead to early onset
MFM reside in the second IPV domain. To gain insight into what
mechanism may underlay this, we initially focused on BAG3P209L
as a prime example of fulminant BAG3-related MFM. The
BAG3P209L mutation has been associated with the aggregation of
sarcomeric proteins, including BAG3P209L itself19. Whereas
BAG3WT was found to be distributed homogenously throughout
the cell, ~50% of myoblast-cells expressing BAG3P209L showed a
punctae-like distribution pattern (Fig. 1b; Supplementary Fig-
ure 1a, b). Similar punctae were observed in HeLa and HEK293
cells upon ectopic expression of BAG3P209L but not of BAG3WT
(Fig. 1c, d). Importantly, BAG3P209L punctae appeared very
similar in all cell types and were reminiscent of cellular aggregates
observed in patients with BAG3P209L-associated MFM/DCM19.
Punctae were strictly cytoplasmic (Fig. 1c and Supplementary
Movie 1 for a 3D visualization) and resistant to pre-fixation
extraction with detergent (Fig. 1d). Indeed, a significant portion
of ectopically expressed BAG3P209L is detergent insoluble in
human cells, whereas BAG3WT is primarily detergent soluble
(Fig. 1e).
Our first hypothesis was that the P209L mutation might
prevent binding of BAG3 to HSPBs because it is located in the
second IPV motif23–25 (Fig. 1a). To test this idea, we measured
the interaction of BAG3WT and BAG3P209L with a model, human
HSPB fragment (HSPB1c/Hsp27c) using isothermal titration
calorimetry (ITC). We found that Hsp27c binding to BAG3P209L
is indeed reduced 3.6-fold as compared to BAG3WT (Fig. 2a).
This loss of affinity was similar to the complete deletion of the
IPV2 motif, but less pronounced than the deletion of both IPV
motifs (Fig. 2a). Further, the estimated stoichiometry (N) of the
complex was reduced from ~2:1 to ~1:1, which is consistent with
the loss of one IPV interaction. To test if this loss of affinity was
sufficient to affect BAG3-HSPB8 interactions in cells, we
performed IPs and found that BAG3P209L binding to HSPB8
was only mildly reduced (Fig. 2b). Rather, it took mutation of
both IPV-motifs (BAG3IPV1mut,IPV2mut) to prevent the interac-
tion. Mutating the first IPV motif in the BAG3P209L background
(BAG3IPV1mut,P209L) did not further affect HSPB8-binding,
supporting the idea that the P209L substitution can still partially
interact with HSPBs (Fig. 2b).
Intriguingly, a complete loss in HSPB binding (BAG3IPV1mut,
IPV2mut) did not affect BAG3 solubility (Fig. 2c; Supplementary
Figure 2a, b) and did not cause formation of BAG3 punctae
(Fig. 2 d, e). Further going against expectations, we noticed that
mutating IPV1 in the presence of the P209L mutation
(BAG3IPV1mut, P209L) only modestly reduced punctae formation
and improved solubility (Fig. 2 c–e; Supplementary Figure 2a, b).
Together, these results surprisingly contradicted the initial
hypothesis and, instead, support the idea that loss of HSPB
binding is insufficient to cause the cellular BAG3P209L phenotype.
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Fig. 2 Protein aggregation by BAG3P209L is not caused by a loss of HSPB binding. a Binding of BAG3 to HSPB1c (Hsp27c) is partially disrupted by P209L.
Binding affinity and estimated stoichiometry were measured by ITC. Results are the average of at least three independent experiments and error is
standard deviation (SD). b Immunoprecipitation from HEK293 cells expressing FLAG-BAG3WT or mutant variants using anti-FLAG beads. Western blots
for FLAG (BAG3) and MYC (HSPB8) is shown. * indicates a cross-reactive band used as loading control. c NP-40 insoluble fraction of HEK293 cells
expressing indicated FLAG-BAG3 variants. Western blot against the indicated antibodies is shown. The soluble fraction can be found in supplemental
figure S2B. d Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or indicated mutants, using a BAG3 antibody (green). Scale bar=
5 μm. e Quantification of the percentage of cells with BAG3 aggregates expressing the indicated variants of BAG3. Data represent the mean and standard
deviation of two independent experiments (at least 100 cells were counted per experiment, Welch t-test was used to calculate the P values, * indicates
P value < 0.05 and ns is not significant). Source data are provided as a Source data file
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Recombinant BAG3P209L forms non-native oligomers. Next, we
considered a model in which the P209L mutation makes the
BAG3 protein prone to aggregation. Using PepFold predictions,
we had noticed that substituting leucine for proline at amino acid
209 was predicted to switch the local secondary structure from
random coil to β-sheet (Fig. 3a). In line with this prediction,
purified BAG3P209L showed a marked increase in Sypro orange
staining (Fig. 3b), indicative of exposed hydrophobic regions.
Also, BAG3P209L—but not BAG3WT—showed a temperature-
dependent increase in staining with the fluorescent β-sheet dye
thioflavin-T (Fig. 3c). To further explore this relative instability,
we measured the melting temperature of BAG3WT and
BAG3P209L by differential scanning fluorimetry (DSF) and found
that BAG3P209L was nearly 4 °C less stable (BAG3WT 49.6 °C ±
0.78 versus BAG3P209L 46 °C ± 0.58). Strikingly, other hydro-
phobic mutations at position 209, such as Ile and Trp, were also
predicted to increase β-sheet content (Supplementary Figure 3a),
and the purified mutants (BAG3P209I and BAG3P209W) were
thioflavin-T positive (Supplementary Figure 3b). In contrast,
mutations predicted in Pepfold to be random coil in this region
such as BAG3P209A, BAG3P209D, BAG3P209G, and BAG3P209K
(Supplementary Figure 3a), were not thioflavin-T positive (Sup-
plementary Figure 3b). Like BAG3P209L, the other mutants had
reduced affinity for Hsp27c (Supplementary Figure 3c), consistent
with loss of the second IPV motif. In summary, hydrophobic
substitutions at the 209-position seemed to create a local, non-
native structure.
Although these results initially suggested that BAG3P209L
might form insoluble aggregates, we found that recombinant
BAG3P209L is soluble under a wide range of conditions and that
its overall fold is indistinguishable from BAG3WT by circular
dichroism (CD) (Fig. 3d). However, in SEC-MALS experiments,
BAG3WT and all control mutants (BAG3P209A, BAG3P209D,
BAG3P209G, and BAG3P209K) were monomeric (~62 kDa),
whereas BAG3P209L and the hydrophobic mutants (BAG3P209I
and BAG3P209W) primarily formed soluble, higher order
oligomers (Supplementary Figure 3d). Indeed, BAG3P209L
showed partial resistance to trypsin digestion and a modest
resistance to chymotrypsin digestion (Fig. 3e), further suggesting
a higher order structure. Consistent with these in vitro data, we
separated detergent-soluble cell lysates on sucrose gradients and
found that BAG3P209L sediments at higher densities than
BAG3WT (Fig. 3f). Together, these results show that BAG3P209L
itself is not prone to forming insoluble aggregates, but that it does
have a non-native quaternary structure.
BAG3P209L is impaired in stimulating HSP70-ATPase activity.
We next wondered how the soluble BAG3P209L oligomers might
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affect its interactions with Hsp70. In vitro and in cells, BAG3 and
Hsp70 are known to coordinate cycles of client-binding and cli-
ent-release, creating the delicate balance required for refold-
ing26,27. To probe for a putative effect of the P209L mutation on
its functional interaction with Hsp70, we initially measured the
affinity of BAG3WT and BAG3P209L for the nucleotide-binding
domain (NBD) of a representative Hsp70 family member,
HSPA8, by ITC. Under these conditions, both BAG3WT and
BAG3P209L bound normally to HSPA8NBD (KD ~ 0.3 µM)
(Fig. 4a). Further, all of the point mutants had normal activity in
releasing fluorescent nucleotide from HSPA8NBD (Fig. 4b).
Together, these data imply that, despite their nonnative qua-
ternary structure, all of the mutants can bind to Hsp70.
Next, we wondered whether the BAG3P209L oligomerization
might have an impact on more complex, biochemical functions.
For example, BAG3 transiently interacts with Hsp70s, such as
HSPA8, during steady state ATP cycling. We found that BAG3WT
shows the expected concentration-dependent bell-shaped curve
for stimulating the ATPase activity of HSPA8, characteristic for
all BAG proteins (Fig. 4c)28. Despite the similar binding affinity,
BAG3P209L was inactive in these ATPase assays (Fig. 4c). This
loss of activity of BAG3P209L was further exacerbated at higher
temperatures, consistent with the ThT and DSF assays. Thus,
BAG3P209L oligomers, despite being able to bind Hsp70, seemed
to have a defect in coordinating its function over time. To
investigate the consequence of this defect, we used denatured
firefly luciferase as a model client protein. We first replicated the
known behavior of BAG3WT, in which low levels (~0.2 µM) of the
co-chaperone enhance the yield of folded luciferase by ~fourfold,
while this stimulatory activity is lost at higher concentrations
(Fig. 4d), mirroring the effect of BAG proteins in the Hsp70-
ATPase assays (see Fig. 4c). Strikingly, BAG3P209L was severely
compromised in this assay, only inhibiting the reaction (Fig. 4d).
To test whether the Hsp70–BAG3P209L axis might be disrupted in
living cells as well, we expressed BAG3WT or BAG3P209L and
measured overall cellular folding capacity. It is known that over-
expression of NEFs, such as BAG3, reduces the cellular luciferase
folding capacity29, likely because NEFs are constitutively
expressed at or near their optimal concentration (e.g., the
equivalent of 0.2 µM in Fig. 4d). Despite this difficult backdrop,
we found that elevated expression of BAG3P209L reduced Hsp70-
mediated folding capacity even further than high levels of
BAG3WT (Fig. 4e). In summary, hydrophobic mutations in BAG3
at position 209 induce a mild temperature dependent local
unfolding that still allows proper Hsp70 binding but stalls the
Hsp70 cycle at the client release stage.
Disruption of Hsp70–BAG3P209L binding rescues aggregation.
Next, we wondered whether the failure to coordinate with Hsp70
might underlie the aggregation phenotype in cells. Therefore, we
deleted the BAG domain, which is required for Hsp70 bind-
ing9,28, from BAG3WT and BAG3P209L and tested whether these
proteins affect aggregation in cells. As controls, we also deleted
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presence of Hsc70, DnaJA2, and various concentrations of BAG3WT or BAG3P209L. Results are the average of at least three independent experiments
performed in triplicate each. Error bars represent SD. e luciferase folding capacity of HEK293 cells expressing HSPB8 and BAG3WT or indicated mutants of
BAG3. Data represents the mean and standard deviation of two independent experiments (with three technical repeats for each experiment, Welch t test
was used to calculate the P values, ** indicates P < 0.01). f Noncanonical interaction of BAG3P209L with LVEAVY amyloid peptide. Source data are provided
as a Source data file
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the WW- and PxxP-domains, which are not involved in Hsp70
binding. When over-expressed in cells, none of the BAG3WT
deletions (BAG3WT−ΔWW, BAG3WT−ΔPxxP, or BAG3WT−ΔBAG)
resulted in punctae formation or insolubility (Fig. 5a–c). Also,
expression of the BAG3P209L−ΔWW and BAG3P209L−ΔPxxP dou-
ble mutants yielded punctae that were indistinguishable from
those caused by BAG3P209L single mutant alone (Fig. 5a–c).
These results suggest that interactions with BAG3-binding part-
ners, such as synaptopodins (WW domain)1 and SH3 domain-
containing proteins, such as dynein motors (PxxP-motif)1, are
not involved. Moreover, loss of Hsp70 interaction alone
(BAG3WT−ΔBAG) is not sufficient to cause an obvious aggrega-
tion phenotype. However, abrogating the ability of BAG3P209L to
interact with Hsp70 (BAG3P209L−ΔBAG), fully prevented punctae
formation and loss of solubility (Fig. 5a–c). Immunoprecipitation
experiments confirmed that BAG3P209L−ΔBAG could no longer
bind Hsp70s (Fig. 5d). These results confirm our in vitro data,
showing that BAG3P209L forms non-native oligomers, but that its
interaction with Hsp70 is required for the formation of visible,
BAG3P209L-related punctae.
The requirement of Hsp70 interaction for BAG3P209L-
mediated aggregation was confirmed by experiments with a
single point mutation, R480A, in the BAG domain (indicated
with an * in Fig. 1a). This BAG3R480A mutant is strongly
impaired in Hsp70 binding (Fig. 5d) but is otherwise normal28.
When expressed in cells, the R480A mutation could suppress the
effects of P209L, as the double mutant (BAG3P209L, R480A) is
neither insoluble (Fig. 5e), nor localized in punctae (Fig. 5a, b).
Further, BAG3P209L, R480A, unlike BAG3P209L, did not have an
adverse effect on the folding capacity in cells (Fig. 4e). To
independently test this idea, we treated BAG3P209L expressing
cells with YM01 and JG98 molecules, which pharmacologically
impair binding of Hsp70 to BAG330. YM01 and JG98 reduce the
affinity of Hsp70 to BAG proteins by trapping the ADP-bound
state, resulting in a partial inhibition (Fig. 5f). Consistent with the
double mutant data, both compounds reduced the BAG3P209L-
associated insolubility in a dose dependent manner (Fig. 5g, h).
Together, these results support the idea that protein aggregation
caused by BAG3P209L requires the recruitment of Hsp70. Thus,
the slight decrease in BAG3P209L stability (Supplementary
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Fig. 5 BAG3P209L aggregation requires an interaction with Hsp70. a Immunofluorescence images of HeLa cells expressing FLAG-BAG3wt and indicated
mutants using an antibody recognizing BAG3 (green). Scale bar= 5 μm. b Quantification of the fraction of HeLa cells expressing the indicated BAG3
variants with immunofluorescence detectable punctae (2 experiments, at least 100 cells were counted per experiment, error bars represent SD, Welch t
test was used to calculate the P values, * indicates P < 0.05). c Western blot of the NP-40 insoluble fraction of HEK293 cells expressing BAG3wt and
indicated variants of BAG3. d Immunoprecipitation of FLAG-BAG3 variants from HEK293 cells expressing both Myc-HSPB8 and indicated FLAG-BAG3
variants. Western blots using the indicated antibodies is shown. e Western blot of NP-40 soluble and insoluble fractions of HEK293 cells expressing
indicated BAG3 variants; FLAG (BAG3), Myc (HSPB8), and tubulin antibodies were used. f Western blot of immunoprecipitates using anti FLAG beads
from HEK293 cells expressing both FLAG-BAG3P209L and Myc-HSPB8 in cells treated with either 0.5 μM JG-98, 5μM YM-01 or DMSO; FLAG (BAG3),
Myc (HSPB8), HSPA1A, and actin antibodies were used. g, hWestern blot of NP-40 soluble and insoluble fractions of HEK293 cells expressing both FLAG-
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10 µM) (h). Source data are provided as a Source data file
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Figure 3d and Fig. 3e) seems to be insufficient to induce
aggregation by itself in vitro (Fig. 3e) or in cells (Fig. 5). Rather,
upon binding to Hsp70, BAG3P209L oligomers are recruited,
along with Hsp70 clients. Then, because BAG3P209L is unable to
stimulate Hsp70-mediated function, we speculate that this
complex stalls and eventually causes co-aggregation. It is difficult
to monitor this type of higher order process in vitro, but we found
that recombinant BAG3P209L (but not BAG3WT) binds unfolded
Hsp70 clients such as the LVEAVY peptide from IAPP (Fig. 4f),
possibly via its non-canonical interaction surface28. Thus, we
envision that multivalent interactions between BAG3P209L,
Hsp70s, HSPBs and clients, driven by aberrant BAG3P209L-client
contacts and avidity effects through multiple BAG domain-
Hsp70NBD contacts may disrupt dynamic protein-protein inter-
actions and trigger aggregation.
BAG3P209L co-aggregates proteasomal substrates. BAG3 has
been found to be upregulated by various forms of stress that
overload the proteasomal capacity11,14 and to redirect ubiquiti-
nated Hsp70-clients from the proteasome to the autophagy-
lysosome system11,31. During this process, termed BAG-induced
proteasome to autophagy switch and sorting (BiPASS), BAG3 and
Hsp70, along with ubiquitinated clients, temporarily localize to
p62/LC3-positve punctae before being degraded by autophagy11.
Intriguingly, the punctae formed by BAG3P209L under nonstress
conditions stain positive for p62, but not LC3B (Fig. 6a), sug-
gesting that, although BAG3P209L remains partially functional in
initiating BIPASS, the process is somehow impaired or stalled.
Indeed, compared to BAG3WT, the ability of BAG3P209L to
support the autophagic disposal of protein aggregates initiated by
polyglutamine (polyQ) was much reduced (Fig. 6b, c; Supple-
mentary Figure 4a)4. This result indicates that delivery of cargo to
the autophagic system is impaired in BAG3P209L-expressing cells.
In-line with this hypothesis, BAG3P209L expression led to the
accumulation of ubiquitin-positive punctae that co-localized with
BAG3P209L (Fig. 6d; Supplementary Figure 4b). Moreover, NP40-
insoluble ubiquitinated proteins accumulated upon BAG3P209L-
expression (Supplementary Figure 4c)11. To further investigate
whether BAG3P209L affects the disposal of proteasomal clients, we
co-expressed the proteasomal reporters Ub-R-GFP (degraded
following proteasome via the N-end-rule pathway25) and GFP-
ODC (delivered to the proteasome via ubiquitin-independent
pathways)32 with BAG3WT or BAG3P209L. Expression of
BAG3WT led to small increases in both reporters (Fig. 6e), which
reflects its role in rerouting proteasomal HSP70-clients to
autophagosomes11. Mirroring its effects on endogenous ubiquitin,
BAG3P209L dramatically increased the levels of both reporters,
revealing a dramatic loss in the cellular capacity to degrade
proteasomal clients. Further, BAG3P209L, but not BAG3WT, led to
the insolubilization of both proteasomal reporters (Fig. 6e).
Experiments using a cell line stably expressing the proteasomal
reporter Ub-G76V-YFP, which is degraded via the UFD-
pathway32, showed qualitatively similar results (Supplementary
Figure 4d). Expression of BAG3IPV1mut, IPV2mut did not lead to
the insolubilization of ubiquitinated proteins or their accumula-
tion in BAG3P209L punctae, while BAG3IPV1mut, P209L led to less
insolubilization and punctae formation of ubiquitinated proteins
than BAG3P209L (Supplementary Figure 4e, f), again showing that
loss of HSPB binding is not responsible for the functional defect
in BAG3P209L. Also, in line with our previous results (Fig. 5),
Hsp70 binding is essential for the dominant defect evoked by
expression of BAG3P209L: besides abrogating the BAG3P209L-
insolubilization itself (Fig. 5), deletion of the BAG domain (but
not the WW or PxxP domain) in the background of the P209L
mutation also negated the BAG3P209L effects on the
insolubilization of ubiquitinated proteins (Supplementary Fig-
ure 4g) and their accumulation into the BAG3P209L punctae
(Supplementary Figure 4b). In addition, the BAG3P209L,R480A
double mutant neither led to the insolubilization of ubiquitinated
proteins (Fig. 6f), nor to the accumulation and precipitation of
the UFD reporter (Supplementary Figure 4d). Finally, JG98 or
YM01 treatment counteracted the effects of BAG3P209L on the
insolubilization of ubiquitinated proteins (Supplementary Fig-
ure 4h, i). Together, these results indicate that BAG3P209L leads to
a general impairment of processing and aggregation of a wide
range of ubiquitin-tagged client proteins of HSPB or/and HSP70.
PQC proteins co-aggregate with BAG3P209L. How the accu-
mulation of aggregates in cells can lead to toxic effects has been a
matter of dispute for many years and may involve several, per-
haps parallel acting, events5. One consequence of aggregation is
the sequestration of components of the PQC systems, which leads
to a vicious and progressive decline in protein homeostasis that
subsequently impairs many cellular functions and eventually
results in cell death5. Indeed, upon expression of BAG3P209L,
we found that in addition to ubiquitinated proteins (Fig. 6) sev-
eral chaperones (HSPA1A, HSPA8, HSPB8, DNAJB1, and
DNAJB6), albeit not all (HSPB5 and HSPA6), to be enriched in
the same detergent-insoluble fraction as BAG3P209L (Fig. 7a;
Supplementary Figure 5a). The same chaperones also co-
localized with BAG3P209L-punctae (Fig. 7b; Supplementary Fig-
ure 5b, c; note that HSPB1 is also colocalizing with BAG3P209L-
punctae). This co-aggregation was also highly dependent on
the BAG3P209L–Hsp70 interaction as disruption of the BAG
domain abrogated the co-aggregation (Fig. 7a; Supplementary
Figure 5a–c). Many DNAJs are known to have their own client-
binding ability that is not dependent on Hsp70-interactions. We
found that the recruitment of DNAJB1 and DNAJB6 into
aggregates is independent of their interaction with Hsp70 as the
DNAJB1H32Q and DNAJB6H31Q mutants still co-localized with
BAG3P209L punctae (Fig. 7c), suggesting that their co-localization
with punctae is Hsp70 independent. One possibility is that co-
chaperones are recruited by clients and trapped when they
become insoluble. In line with such a trapping model, only
the mainly cytosolic DNAJB6 isoform (DNAJB6b, 26 kDa)
became insoluble in BAG3P209L-expressing cells, while the
exclusively nuclear isoform (DNAJB6a, 40 kDa) remained soluble
(Fig. 7a).
Sequestration of chaperones suppresses their function. Trap-
ping of (co-)chaperones could contribute to disease by reducing
their effective pool in the cell. To test this idea, we measured the
ability of DNAJB6b to suppress polyQ aggregation in the back-
ground of BAG3WT or BAG3 mutants. BAG3WT can reduce
aggregation initiated by polyQ74 expansions (Fig. 6)4 but not
aggregation initiated by extremely long polyQ119 fragments, while
DNAJB6 co-expression alone almost completely suppresses
polyQ119 aggregation (Fig. 7d)33,34. In line with the hypothesis of
a dominant negative effect via sequestration of other chaperones
into BAG3P209L aggregates, co-expression of BAG3P209L—but not
BAG3WT or BAG3P209L, R480A—inhibited DNAJB6-mediated
anti-aggregation (Fig. 7d). Together, these data reveal that
BAG3P209L directly stalls the Hsp70 function, which—as a result
—perpetuates into a dominant effect on the function of other
chaperones.
Stalling of HSP70 in other BAG3-related MFM mutations. To
test if impediment of Hsp70 functioning by single amino acid
substitutions in BAG3 occurs more frequently, we turned to two
other mutations at the P209 position, BAG3P209Q, and
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BAG3P209S that cause MFM or neuropathy, respectively21,22. Like
BAG3P209L, both BAG3P209Q and BAG3P209QS form multiple
punctae when expressed in cells (Fig. 8a). Likewise, genetic
abrogation of the Hsp70 interaction (BAGR480A,P209Q BAG3P209S,
R480A) reverts this phenotype as well (Fig. 8a, b), implying that all
P209 disease-causing mutants operate via a similar dominant
Hsp70-stalling mechanism.
In order to further understand BAG3 associated MFM
pathogenesis and identify potentially novel BAG3 genetic variants
that are associated with MFM, we performed exome sequencing
on patients with muscle weakness and features of MFM on
muscle biopsy. This approach identified two unrelated MFM
patients carrying an unreported BAG3 c.1408C>T; p.P470S
missense mutation (Supplementary Figure 6a). Neither patients
had a family history of muscle weakness or other neuromuscular
disorder. Whole exome sequencing of patient 2’s living parents
failed to identify the BAG3 c.1408C>T; p.P470S variant,
suggesting that it was a de novo mutation in this patient. It was
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Fig. 6 BAG3P209L aggregation leads to co-aggregation of proteasomal substrates. a Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT
or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Scale bar= 5 μm. b Suppression of GFP-HttQ74 aggregation of cells
expressing a control, FLAG-BAG3WT or FLAG-BAG3P209L. Western blot against indicated antibodies is shown. c Quantification of GFP-HttQ74 aggregation
of experiments similar to b. Relative percentage of SDS-insoluble protein levels are shown. Data represents the mean and standard deviation of three
independent experiments. d Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3
(green) or ubiquitin (red). Left column BAG3, middle column ubiquitin and right column is the merge of BAG3 (green), ubiquitin (red), and DAPI (blue).
Scale bar= 5 μm. e Fractionation of HEK293 cells expressing HSPB8, a control or BAG3WT or BAG3P209L, together with either Ub-R-GFP or GFP-ODC
(ornithine decarboxylase). Western blot against GFP, FLAG (BAG3), Myc (HSPB8), and tubulin are shown. f Fractionation of HEK293 cells expressing
HSPB8 and indicated BAG3 variants. Western blot using ubiquitin (FK2) and tubulin antibodies are shown. The same samples as in Fig. 5e have been used,
loading control is therefore the same. Source data are provided as a Source data file
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only possible to obtain DNA samples from Patient 1’s mother,
confirming that she was a nonvariant carrier (Fig. 8c). Muscle
tissue from both patients demonstrated features characteristic for
MFM patient tissue with sarcoplasmic inclusions and rimmed
vacuoles as visualized on hematoxylin and eosin staining and
gomori trichrome (Fig. 8d).
Amino acid P470 is conserved in all human BAG proteins,
except BAG2, and amongst various BAG3 from other vertebrate
species (Supplementary Figure 6b). The P470S variant is
predicted to be damaging by Polyphen2 and Mutation Taster.
Moreover, it is not found within public databases, including the
EXAC browser and GNOMAD, further supporting its patho-
genicity. Unlike the previously reported BAG3 mutations, which
reside within the second IPV motif, the P470 residue lies within
the HSP70 binding region or BAG domain. Since our proposed
model of BAG3 mutant dysfunction suggested that mutations in
the IPV motif destabilize the protein and alter HSP70 kinetics
that require HSP70 binding, we tested whether the P470S
missense mutation within the BAG domain has affected HSP70
binding as well. Surprisingly, the BAG3P470S mutant maintained
HSP70 association, albeit with a slight loss in binding, unlike the
BAG3R480A mutant that abolishes HSP70 binding (Fig. 8e). In
addition, similar to BAG3P209L, BAG3P209Q, and BAG3P209S,
BAG3P470S aggregated in cell culture, which was corrected by a
secondary R480A mutation (Fig. 8a, b). Together these results
suggest that all MFM related BAG3-mutants tested require
interaction with Hsp70 to become pathological and result in a
dominant gain of impairment of the functions of Hsp70-related
networks.
Abrogation of BAG3–Hsp70 by pharmaceutical intervention.
To address whether endogenous, rather than over-expressed,
BAG3 mutations results in similar phenotypes, we performed
experiments with fibroblasts derived from control patients or
patients carrying the BAG3P209L and BAG3P470S mutations.
Endogenous expression of BAG3 is low in most cell types,
including fibroblasts, which may be the reason why no sponta-
neous mutant BAG3-related punctae were observed in the patient
fibroblasts (Fig. 9a, b). However, as stated above, BAG3 is the
only stress-inducible BAG–protein35 and is upregulated by a
variety of stress signaling cascades, including those initiated by
treatment with proteasome inhibitors11. Indeed, a short treatment
with bortezomib produced persistent ubiquitin-positive BAG3
punctae in fibroblasts from both BAG3P209L and BAGP470S car-
riers but not in fibroblasts from patients without the mutation
(Fig. 9a, b). To test whether this punctae formation can be
reversed by disrupting BAG3–Hsp70 interactions, we co-treated
the BAG3 mutated, MFM patient-derived fibroblasts with bor-
tezomib and the drug JG98 that disturbs Hsp70–BAG3
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interactions (Fig. 5f) and reverts aggregates formation when the
mutants are overexpressed (Fig. 5, Supplementary Figure 4). As
predicted, this treatment indeed reduced the frequency of per-
sistent BAG3 punctae in the lines from both BAG3P209L and
BAGP470S carriers (Fig. 9a, b). This confirms that they cause
aggregation via similar mechanisms and imply that pharmaceu-
tically targeting the Hsp70–Bag3 interaction could be a first
therapeutic strategy for patients carrying P209L/Q/S or P470S
substitutions.
Discussion
Mutations in BAG3 are associated with a devastating syndrome
that includes MFM, dilated cardiomyopathy, and neuropathy.
Why certain mutations result in a more severe clinical outcome is
unclear. Thus far MFM was associated with mutations at P209
position that lies in the second IPV motif19,36–38. Here, we
describe a second mutation site (P470S) that lies in the BAG
domain. The notion that both are localized in domains that
connect this central co-chaperone to other chaperone systems
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initially led us to hypothesize that the mutation might block
binding to HSPBs or Hsp70, leading to loss-of-function as has
been suggested. However, our results suggest a more nuanced
mechanism characterized by only mildly impaired chaperone
binding but a more intense outcome, i.e., a dramatic stalling of
Hsp70 client processing via a disruption in their ability to func-
tionally stimulates the ATP activity of HSP70s. In cells, these
molecular defects subsequently result in the formation of protein
aggregates via interactions with Hsp70. These aggregates next
trap chaperones that become partly nonfunctional, which is
exemplified by the BAG3P209L-effects on DNAJB6 function.
Intriguingly, just like BAG3 mutations, mutations in DNAJB6
have been linked to myopathies as well39,40.
Interestingly, whereas absence or loss of function of BAG3
result in an increase in insoluble proteins41, this is not sufficient
to cause the formation of large aggregates triggered by
BAG3P209L, BAG3P209Q, BAG3P209S or BAG3P470S mutations.
Apparently, loss (or partial loss) of BAG3 function does affect
PQC, but dominant gain of function mutations, including the
MFM-related BAG3 mutations, are more deleterious by triggering
the negative spiral of trapping and co-aggregating of Hsp70-cli-
ents, Hsp70 itself, and other PQC components. The latter results
in loss of function of other chaperones. Our data reveal a novel
molecular mechanism that would explain the far more pro-
gressive and early onset aspects related to MFM pathology. This
concept has potentially broad implications because multiple
myopathies and neuropathies are caused by dominant mutations
in PQC components as well.
It is also interesting to compare the BAG3-related diseases to
other chaperonopathies, like those caused by recessive or domi-
nant mutations in other Hsp70 co-chaperones such as DNAJ or
HSPB proteins (Supplementary Figure 7a)17. Mutations in
DNAJs or HSPBs are typically associated with late onset cardio-
myopathies or neuropathies. In contrast, mutations in the NEFs
(Sil-1 and BAG3) often cause early onset or congenital
disease18,19,22,36–38. The reason for this is not known but could
reside in the fact that DNAJs and HSPBs primarily select the
input of clients into Hsp70 chaperones machines (Supplementary
Figure 7b). This implies that only a certain number of substrates
are affected. Moreover, the handling of these substrates can, at
least for some time, be taken care of by alternative PQC
mechanisms as has been suggested for DNAJB6 mutations42. In
contrast, mutations in BAG proteins, as being NEFs, are
responsible for the output of a larger range and number of sub-
strates (Supplementary Figure 7b). Therefore, impairment of NEF
functions like that of Sil1 and BAG3 may impede on more clients
and thus have a more drastic impact. For, BAG3 loss of hetero-
zygosity already leads to widespread and early onset
diseases19,22,36–38. Even more so, BAG3 is involved in what
already seems to be a back-up PQC mechanism that compensates
for an overload of the proteasome (BIPASS)11.
The high vulnerability of skeletal and cardiac muscle cells to
BAG3 mutations may be linked to the fact that BAG3 is con-
stitutively expressed at relatively high levels in these tissues. Stress
situations that overload the proteasome increase BAG3 levels
without affecting expression of other members of the BAG family35,
probably helping cells to reroute proteasomal clients to autopha-
gosomes11. Muscle cells are repeatedly exposed to cellular stress
(e.g., mechanic stress from exercise) that may elevate BAG3
expression to levels sufficient for the primary defects of mutants,
like BAG3P209L, to start take effect. Among the BAG family
members, BAG3 has the highest affinity for Hsp70s27,
meaning that a stress-related imbalance in relative BAG levels
may suffice to initiate the negative cascade described here. Indeed,
the data on patient-derived fibroblasts provides a proof-of-concept
for this idea.
These results suggest that either genetic or small molecule
perturbation of the Hsp70–BAG3 interaction might not only
attenuate the aggregation cascade but also minimize its toxic,
downstream effects. This result suggests that the Hsp70–BAG3
contact could be a drug target for the treatment of BAG3-related
myopathies. Indeed inhibitors of this interaction, have been
advanced to preclinical safety studies in mice27. However, any
such treatment for human myopathy would require long-term
administration and the safety of disrupting a central chaperone
activity is not yet clear. Nevertheless, our results suggest that
further development of more specific inhibitors of the
BAG3–Hsp70 interaction, for example ones that selectively target
the mutant BAG3–Hsp70 interaction, may be promising.
Methods
Plasmid construction. Plasmids encoding myc-tagged human HSPB843 and
peGFP-HDQ74, were kindly provided by Dr. D.C. Rubinsztein44. FLAG-BAG3
WT and P209L constructs were kindly provided by Dr. S. Takayama. The primers
and plasmids used in this study are listed in Supplementary Table 1 and Supple-
mentary Table 2. To generate Flag tagged human BAG3 (pcDNA3 FLAG-BAG3),
BAG3 delta BAG (pcDNA3 FLAG-BAG3ΔBAG), and BAG3 delta PxxP (pcDNA3
FLAG-BAG3ΔPxxP), the BAG3 encoding sequences of the following constructs were
amplified by polymerase chain reaction (PCR) with Phusion polymerase, purified
by agarose gel electrophoresis and ligated to EcoRI and XhoI digested pcDNA
FLAG-Parkin: BAG3 (pCN His-BAG3), BAG3 ΔBAG (pCN His-BAG3ΔBAG) and
BAG3 ΔPxxP (pCN His-BAG3ΔPxxP). Using specific primers, the P209L mutation
was introduced into Flag-tagged BAG3 constructs with the Pfu turbo DNA poly-
merase site directed mutagenesis kit to generate the following constructs:
BAG3P209L (pcDNA3 FLAG-BAG3P209L), BAG3 delta BAG P209L (pcDNA3
FLAG-BAG3ΔBAG, P209L), BAG3 delta PxxP P209L (pcDNA3 FLAG-BAG3ΔPxxP,
P209L), BAG3 delta WW (pcDNA3 FLAG-BAG3ΔWW), and BAG3 delta WW
P209L (pcDNA3 FLAG-BAG3ΔWW, P209L). BAG3 IPV1 (pcDNA3 FLAG-
BAG3IPV1>AAA), BAG3 IPV2 (pcDNA3 FLAG-BAG3IPV2>AAA), BAG3 IPV1
P209L (pcDNA3 FLAG-BAG3IPV1>AAA, P209L), and BAG3 IPV1 IPV2 (pcDNA3
FLAG-BAG3IPV1>AAA, IPV2>AAA) were constructed in a similar fashion; all con-
structs were sequence verified. All domain deletion constructs used for in vitro
studies were subcloned from the BAG3 pMCSG7 parent vector and confirmed with
DNA sequencing. Mutations were constructed using standard mutagenesis
protocols.
Recombinant protein production. All constructs were transformed into BL21
(DE3) cells and single colonies were used to inoculate TB medium containing
ampicillin (50 μg/mL). Cultures were grown at 37 °C to an OD600 0.6, when NaCl
and betain were added to a final concentration of 500 and 10 mM, respectively. The
cultures were cooled to 18 °C and induced overnight with 500 μM IPTG. BAG3-
expressing cells were pelleted, resuspended in BAG3 lysis buffer (50 mM Tris,
100 mM NaCl, 1 mM EDTA, and 15 mM β-mercaptoethanol (pH 8.0)), micro-
fluidized, and applied to Ni-NTA resin. After Ni-NTA columns, all proteins were
subjected to TEV protease cleavage overnight and dialyzed into MonoQ buffer A
(20 mM HEPES, 10 mM NaCl, and 15 mM β-Mercapthoethanol (pH 7.6)). Pro-
teins were applied to a MonoQ column (GE Healthcare) and eluted by a linear
gradient of MonoQ buffer B (buffer A+ 1M NaCl). Fractions were dialyzed into
BAG buffer (25 mM HEPES, 5 mM MgCl2, and 150 mM KCl (pH 7.5)) and con-
centrated. Hsc70, Hsc70NBD, Hsc70SBD, J proteins, and Hsp27c were purified using
a His column and subsequent SEC on a Superdex S2009. Further details are pro-
vided in the Supplementary Methods.
DSF and ThT melt curve. Samples of BAG3WT or BAG3P209L in BAG3 buffer
(20 μL samples of 0.3 mg/mL) with a 5× final concentration of SYPRO Orange
(Sigma) were placed into a white 96-well plate with optically clear caps. DSF melt
curves were acquired on a Stratagene Mx300P RT-PCR using the SYPRO filter set.
Samples were heated from 25 to 95 °C in 1 °C increments, and the melting tem-
perature was determined using a Boltzmann fit. For ThT melt curves, 100 μL
samples of 10 μM BAG3WT or BAG3P209L with 10 µM ThT were heated in a
thermocycler from 20 to 90 °C in 10 °C increments and removed from heating at
each temperature. Samples were cooled to 20 °C and plated in a low volume, black
384-well plate (Corning) and ThT fluorescence was read with 444 nm excitation,
485 nm emission, and a 475 nm cutoff using a SpectraMax5 M5 multi-mode plate
reader. All experimental data were analyzed using Prism 7.0 software (Graphpad
Software).
CD. BAG3WT and BAG3P209L were dialyzed overnight against 20 mM NaPi with
100 mM NaF (pH 7.5). 0.1 mg/mL samples were placed in a low-volume (250 μL)
cuvette. Measurements were taken at 25 °C using a Jasco710 instrument.
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Partial proteolysis. BAG3WT or BAG3P209L (0.8 mg/mL or ~13 μM) in BAG
buffer was subjected to partial proteolysis with either chymotrypsin (1/5000 ratio
BAG3/enzyme) or trypsin (1/10,000). The samples were incubated at 37 °C for
specified time and reactions were quenched by adding sodium dodecyl sulfate
(SDS) sample loading dye and boiling at 98 °C for 5 min. Protein fragments were
separated by SDS–polyacrylamide gel electrophoresis (PAGE) and stained with
Coomassie.
ITC. BAG3 constructs, Hsp27c and Hsp72NBD were dialyzed overnight against ITC
buffer (25 mM HEPES, 5 mM MgCl2, 100 mM KCl [pH 7.5]). Concentrations were
determined using a BCA Assay (Thermo Scientific), and the experiment was
performed with a MicroCal microITC (GE Healthcare) at 25 °C. Hsp72NBD
(100 μM) or Hsp27c (200 μM) in the syringe was titrated into a 10 μM cell solution
of BAG3 protein. Calorimetric parameters were calculated using Origin® 7.0 soft-
ware and fit with a one-site binding model.
Antibodies and reagents. Antibodies (dilutions are indicated in brackets for
western blot (WB), immunofluorescence (IF), or immunoprecipitation (IP))
against FLAG (Sigma, clone M2; Sigma, produced in Rabbit, IP 3 μl/sample, IF
1:100, WB 1:1000), FLAG (Sigma, clone M2; Sigma, M, Wb 1:1000, IF 1:200),
ubiquityl-histone H2A (Millipore, clone E6C5), ubiquitin (Norvus Biologicals, FK2,
M, WB 1:1000, IF 1:1000; Dako WB), K48-linkage specific polyubiquitin (Enzo
lifesciences, WB 1:1000), K63-linkage specific polyubiquitin (Cell Signaling, clone
D7A11, 1:1000), myc (MBL, clone PL14, WB 1:3000, IF 1:100), HSC70 (Stressgen,
WB 1:5000, IF 1:100), LC3B (Novus Biologicals, NB100-220), GFP (clonetech,
632381), p62 (Enzo Life Sciences, BML-PW9860), Lamin A/C (Santa Cruz, 4A58),
HSC70 (Stressmarq biosciences), HSP70 (Stressgen, clone SPA-810, WB 1:1000, IF
1:50), HSPA1A (Enzo life sciences, Rb, WB 1:1000), HSPB1 (Stressmarq bios-
ciences), GAPDH (Fitzgerald, clone 6C5, WB 1:50,000), histone H2A (Abcam, WB
1:5000), MYC (Clonetech, Mountain View, CA, USA), and DNAJB1/Hsp40
(Stressgen, San Diego, CA, USA, Rb, 1:1000) were used.
MG132 (20 µM for 3–6 h), rapamycin, Pepstatin A (10 μg/ml), E64d (10 μg/ml),
3-methyladenine (3-MA, 10 mM) ammonium chloride (NH4Cl, 20 mM) were
from sigma.
Cell culture and transfection. Standard cell culture techniques were used. HeLa
(human cervical cancer), HEK293, and HEK293T (human embryonal kidney) cells
were grown at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium with high
glucose supplemented with 10% fetal calf serum and 1% penicillin/streptomycin
(Gibco). LHCNM2 human myoblasts were cultured in HAM’s F12, supplemented
with 20% FBS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin and 25 ng/mL
of rh FGF-b/FGF-245. Cell lines stably expressing GFP-ubiquitin (kind gift of Dr.
Dantuma) were generated by transfecting GFP-ubiquitin into HEK293-cells with
lipofectamine using standard procedures. HEK293T and HeLa-cells were trans-
fected with calcium phosphate precipitation, or with lipofectamine (Invitrogen) or
polyethylenimine (PEI) (Sigma-Aldrich, St. Louis, MO, USA) according to man-
ufacturer’s protocols.
Chaperone assays. The steady-state ATPase activity of Hsc70 was measured by
malachite green as previously reported46. For ATPase activity, Hsc70 (final con-
centration 1 µM), DnaJA2 (final concentration 0.5 µM) and various concentrations
of BAG3 WT or P209L were added to clear 96-well plates to give a volume of 15 µL.
The reaction was initiated by adding 10 μL of 2.5 mM ATP to give a final con-
centration of 1 mM. Plates were covered and incubated at 37 °C for 1 h. The
reactions were developed with malachite green, quenched with sodium citrate, and
plate absorbance was measured at 620 nm.
Luciferase refolding assay. The refolding of chemically denatured firefly luci-
ferase was measured by recovered luminescence27. Briefly, working stocks of
denatured luciferase were prepared by mixing 10 μL of 200 μM native firefly
luciferase (Promega) with 30 μL of 8 M GnHCl for 1 h at room temperature.
Denatured luciferase stocks were stored at −80 °C until use. To white 96-well
plates, was added denatured luciferase (final concentration of 100 nM), Hsc70
(final concentration of 1 µM), DnaJB4 (final concentration of 0.5 µM), and various
concentrations of BAG3WT or BAG3P209L to give a final volume of 25 μL in
refolding buffer (20 mM HEPES, 120 mM KAc, 1.2 mM MgAc, 15 mM DTT,
60 mM creatine phosphate, 35 U/mL creatine kinase, 5 ng/μL BSA, pH 7.4). The
reaction was initiated by adding 10 μL of 2.5 mM ATP to give a final concentration
of 1 mM. Plates were covered and incubated at 37 °C for 1 h. Finally, 25 μL of
Steady-Glo reagent (Promega) was added to each well and luminescence values
were measured immediately.
SEC-MALS. Solutions of BAG3WT or BAG3P209L (30 µM) were separated by size
exclusion chromatography (Shodex 804), as previously described9. Molecular
weights were determined by multi-angle laser light scattering using an in-line
DAWN HELEOS detector and an Optilab rEX differential refractive index detector
(Wyatt Technology Corporation). Calculation of molecular weights was performed
using the ASTRA software package (Wyatt Technology Corporation).
Fluorescent peptide assay. Experiments were performed in 384-well, black, low
volume, round-bottom plates (Corning) using a SpectraMax5 M5 multi-mode plate
reader47. To each well, was added specified amount of protein and the 5-
carboxyfluorescein (5-FAM) labeled LVEALY tracer (20 nM) to a final volume of
20 μL in the assay buffer (50 mM HEPES, 75 mM NaCl, 0.01% Triton X-100, pH
7.4). The plate was incubated at room temperature for 30 min to reach equilibrium.
The polarization values in millipolarization units (mP) were measured at an
excitation wavelength at 485 nm and an emission wavelength at 535 nm.
Protein-pull down. For IP, cells were lysed on ice in IP lysis buffer 24 h post-
transfection (buffer: 60/80 mM KCl, 50 mM HEPES pH 7.5, 1.5 mM MgCl2, 0.4%
Nonidet P-40, 10/3% glycerol, 0.5 mM DTT, complete EDTA-free (Roche Applied
Sciences) and 10 mM NEM). Cell lysates were homogenized by passing lysates 5/6
times through a 26 G needle and the total or “whole cell lysate” was collected.
Lysates were centrifuged at maximum speed for 15 min at 4 °C in order to separate
the supernatant (input or soluble fraction) from the pellet fraction (insoluble
fraction). The protein concentration was determined (using DC™ protein assay kit
from Bio-Rad) and input fractions were equalized. In the meantime, magnetic
beads complexed with FLAG-antibodies (14 μl beads/sample; Sigma, FLAG M2,
clone) were washed with IP lysis buffer. Pellet fractions were resolubilized with 2%
SDS buffer containing beta-mercapthoethanol, boiled, and stored for future use.
Co-IP was performed by adding equal amounts of input fraction onto the washed
magnetic beads and incubating them at slow rotation (5 RPM) for at least 2 h at 4 °
C. The first wash was performed using the IP-volume in lysis buffer and a magnetic
stand. In between washes, beads were incubated on the rotator for 5 min at slow
rotation at 4 °C. Further three washes were performed in a similar way using 1 mL
of IP lysis buffer. During the last wash, beads were transferred into new cups and
washed with IP lysis buffer without detergent. Proteins were eluted using ½ volume
2% SDS buffer and ½ volume 4 × 2% SDS buffer and 10% beta-mercapthoethanol.
Samples were kept on ice until they were boiled for 5 min co-immunoprecipitated
proteins and input fractions were resolved on SDS-PAGE the same day as the IP
was performed.
Fractionations. Protein measurement was performed using the nanophotometer
(Implen), protein content was equalized and equal amounts of volume and protein
were used for subsequent fractionation. SDS fractionation was performed as pre-
viously described34,48. For NP40 fractionations, cell-pellets were resuspended in
NP40 fractionation buffer (fractionation buffer: 50mM HEPES, pH 7.4, 2mM
MgCl2, 60mM KCl, 0.4% NP-40, 10% glycerol, complete EDTA-free (Roche,
11873580001) and 10mM NEM). The cell extracts were homogenized by sonication
for 5 s. NP-40 soluble and insoluble fractions were separated by centrifugation at
14,000 RPM for 20 min at 4 °C. Whole cell lysates (precentrifugation), soluble
(supernatant, postcentrifugation), and insoluble fractions (pellet fraction and
postcentrifugation) were captured, supplied with SDS, boiled and resolved on
SDS–PAGE.
Filter trap assay. To determine protein aggregation, the filter trap assay was
performed34. Briefly, cell lysates were made one day after transfection in FTA
buffer (10mM Tris-Cl, 150mM NaCl; pH= 8.0) containing 2% SDS. Serial dilu-
tions of the protein extracts (typically 1:5 and 1:25) were applied onto a 0.2μm pore
cellulose–acetate membrane prewashed with FTA-buffer containing 0.1% SDS.
Aggregated proteins trapped in the membrane were immuno-detected using mouse
anti-GFP antibody JL-8 (Clontech) and visualized as in WB.
Western blotting. Following the preparation of protein samples, proteins were
resolved by SDS-PAGE, transferred to nitrocellulose membrane and processed for
WB. Primary antibodies (at concentrations mentioned above) were prepared in 3%
BSA/PBS-Tween, secondary antibodies (Invitrogen, horse peroxidase conjugated
IGG or IGM) in 5% milk/PBS-Tween. For visualization membranes were incubated
with ECL western blotting substrate (Pierce, cat. No. 32106) for 2 min and
developed (Sigma, cat. No. P7042-1GA) and fixed (Sigma, cat. No. P7167-1GA)
using luminescent films (Amersham hyperfilm, GE-healthcare, cat. No. 28906837).
Quantification of western blots was done using Image lab 5.0 software.
Immunofluorescence. HeLa cells were seeded on poly-D-lysine coated glass slides
and fixed 48 h posttransfection. HeLa cells were washed once with PBS (Gibco) and
fixed with 2% formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) for 15 min at
room temperature. Cells were washed with PBS and PBS+ (PBS with 0.5% BSA
and 0.15% glycine)34,49. Primary antibody incubation was performed overnight at
4 °C in a humid chamber and Alexa-conjugated dyes (Invitrogen, Carlsbad, CA,
USA; Alexa Fluor 488 goat-anti-Rabbit, Alexa Fluor 488 donkey-anti-Rabbit, Alexa
Fluor 594 goat-anti-Rabbit, Alexa Fluor 594 donkey-anti-Rabbit, Alexa Fluor 488
goat-anti-mouse, Alexa Fluor 594 goat-anti-mouse, and Alexa Fluor 594 chicken-
anti-rat) were applied for 1.5 h at room temperature to visualize primary anti-
bodies. Nuclear counterstaining was performed with 4′,6-diamidino-2-pheny-
lindole (DAPI; Invitrogen) or Hoechst 33258 for 5 min, and samples were and
embedded in glycerol (CitiFluor, Agar Scientific). LHCNM2 cells were grown on
poly-L-lysine coated glass coverslip. 24 h after seeding, cells were transfected using
lipofectamine 3000 according to manufacturer protocol. After 24 h transfection,
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cells were fixed with 3.7% formaldehyde for 9 min at room temperature, per-
meabilized with cold (−20 °C) acetone for 5 min at −20 °C. Cells were rinsed with
PBS 1× and processed for immunostaining.
Imaging. IF images were captured using confocal laser scanning microscope (Leica
TCS SP8) with a 63×/1.40 objective lens. Z-stack images were obtained to check for
the aggregates in different Z-planes. Quantification of the aggregates in various
mutants was carried out manually using Leica DM6000 microscope. Imaris,
photoshop, and Image J software was used for image processing.
Clinical data. Standard protocol approvals, registrations, and patient consents.
Clinical data and sample collection: The families were seen by one of the authors
(S.S.S. or C.C.W.) in an outpatient clinic, where clinical neurophysiology was also
performed.
Clinical data and sample collection. IRB approval was obtained from the Uni-
versity of Pennsylvania for these studies. Written informed consent was obtained
from each patient that participated. Each family member was seen by one of the
authors (S.S.S., or C.C.W.) in an outpatient clinic, where clinical neurophysiology
was performed with standard methods.
Whole-exome sequencing and analysis. Genomic DNA was isolated from per-
ipheral blood from all participants. Exome DNA was captured using the SureSelect,
Human All Exon5 50 Mb kit (Agilent, Stanta Clara, CA) and sequenced on a HiSeq
2000 (Illumina, San Diego, CA). Paired-end reads of 100 bp length were generated
and alignment and variant calls were made using BWA51 and GATK software
packages50. Data were then imported into GEM.app, a web-based collaborative
genome analysis tool52, where variants were filtered for de novo non-synonymous
or splice site variants with frequency in public databases (MAF < 0.01 in NHLBI
EVS), conservation (GERP > 2, PhastCons Score > 0.5, or phyloP Score > 0.75). The
BAG3 variant was confirmed by bidirectional Sanger sequencing using forward
(CCCAAGAGTGTGGCTACAGAA) and reverse (GTGTGGGGATCTTCTGCA
TT) primers.
Data availability
The datasets and other data generated during the current study are available from
the corresponding authors upon reasonable request. A Reporting Summary for this
Article is available as a Supplementary Information file. The source data underlying
the figures and Supplementary figures are provided as Source Data file.
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